Market Outlook
The global Pandemic Influenza Vaccine market size was valued at USD 8056.5 million in 2022 and is forecast to a readjusted size of USD 11570 million by 2029 with a CAGR of 5.3% during review period.
Report includes an overview of the development of the Pandemic Influenza Vaccine industry chain, the market status of 6 Months to 3 Years (Trivalent Influenza Vaccine, Quadrivalent Influenza Vaccine), > 3 Years (Trivalent Influenza Vaccine, Quadrivalent Influenza Vaccine), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Pandemic Influenza Vaccine.
Global key players of Pandemic Influenza Vaccine include Sanofi, CSL and GSK, etc. The top five players hold a share about 75%. North America is the largest market, has a share about 50%.
Regionally, the report analyzes the Pandemic Influenza Vaccine markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Pandemic Influenza Vaccine market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Pandemic Influenza Vaccine market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Pandemic Influenza Vaccine industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (M Units), revenue generated, and market share of different by Type (e.g., Trivalent Influenza Vaccine, Quadrivalent Influenza Vaccine).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Pandemic Influenza Vaccine market.
Regional Analysis: The report involves examining the Pandemic Influenza Vaccine market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Pandemic Influenza Vaccine market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Pandemic Influenza Vaccine:
Company Analysis: Report covers individual Pandemic Influenza Vaccine manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behavior, preferences, and attitudes towards Pandemic Influenza Vaccine This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (6 Months to 3 Years, > 3 Years).
Technology Analysis: Report covers specific technologies relevant to Pandemic Influenza Vaccine. It assesses the current state, advancements, and potential future developments in Pandemic Influenza Vaccine areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Pandemic Influenza Vaccine market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Key Market Players
Sanofi
CSL
GSK
Viatris
AstraZeneca
Hualan Bio
Changchun Institute of Biological
Sinovac
BCHT
Jiangsu GDK
KM Biologics
Segmentation By Type
Trivalent Influenza Vaccine
Quadrivalent Influenza Vaccine
Segmentation By Application
6 Months to 3 Years
> 3 Years
Segmentation By Region
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Market SWOT Analysis
What are the strengths of the Pandemic Influenza Vaccine Market in 2025?
The pandemic influenza vaccine market in 2025 will benefit from advancements in vaccine technology, increased production capabilities, and better global distribution networks. These strengths will allow for faster and more efficient response to future influenza outbreaks, ensuring vaccines are readily available to populations at risk.
What weaknesses might the Pandemic Influenza Vaccine Market face in 2025?
Despite progress, challenges such as vaccine hesitancy, the complexity of rapid vaccine development, and issues with equitable distribution could still hinder market growth. Furthermore, the cost of developing and manufacturing vaccines in large quantities may create barriers, especially in low-resource settings.
What opportunities exist for the Pandemic Influenza Vaccine Market in 2025?
The growing focus on pandemic preparedness and the increasing importance of influenza vaccination programs worldwide presents significant opportunities for market expansion. Innovations like mRNA technology and the potential for universal flu vaccines are also exciting avenues for growth, improving the effectiveness and reach of vaccines.
What threats could impact the Pandemic Influenza Vaccine Market in 2025?
Emerging viral strains that could evade current vaccines represent a major threat. Additionally, geopolitical tensions and supply chain disruptions could delay vaccine distribution. Competition from other vaccine manufacturers and alternative treatments might also limit the market share of traditional influenza vaccines.
Market PESTEL Analysis
What political factors will affect the Pandemic Influenza Vaccine Market in 2025?
Government policies regarding vaccine regulations, funding for research and development, and international cooperation for pandemic preparedness will significantly impact the market. Political stability and the prioritization of public health will play crucial roles in ensuring timely production and distribution of vaccines.
How will economic factors influence the Pandemic Influenza Vaccine Market in 2025?
Economic conditions, such as global economic stability and healthcare spending, will affect the affordability and accessibility of pandemic influenza vaccines. Economic downturns could lead to reduced public health budgets, while growing economies may invest more in research and vaccine stockpiling.
What social factors should be considered in the Pandemic Influenza Vaccine Market in 2025?
Public perception of vaccines, vaccine hesitancy, and societal awareness of pandemic risks will influence vaccine adoption rates. Education campaigns and trust in health authorities will be critical to encouraging mass vaccination, especially in regions with low vaccination coverage.
What technological factors will shape the Pandemic Influenza Vaccine Market in 2025?
Advancements in vaccine development technologies, such as mRNA platforms and quicker production methods, will revolutionize the market. Innovations in storage and distribution (e.g., temperature-sensitive vaccines) will enhance global reach, ensuring vaccines can be delivered to remote areas more efficiently.
How will environmental factors affect the Pandemic Influenza Vaccine Market in 2025?
Climate change and environmental disruptions may contribute to the spread of infectious diseases, leading to a greater demand for pandemic vaccines. Additionally, sustainable vaccine production practices and eco-friendly packaging will become more important as the industry faces increasing pressure to reduce its carbon footprint.
What legal factors must be taken into account in the Pandemic Influenza Vaccine Market in 2025?
Regulations regarding vaccine approval, intellectual property rights, and liability for vaccine-related injuries will influence the market. Legal frameworks for global cooperation and vaccine distribution during pandemics will also be critical to ensuring timely and equitable access to vaccines.
Market SIPOC Analysis
Who are the suppliers in the Pandemic Influenza Vaccine Market in 2025?
Suppliers in this market include pharmaceutical companies, raw material suppliers (e.g., antigens, adjuvants, and excipients), contract manufacturers, and biotechnology firms. These suppliers provide the necessary resources for vaccine development and production.
What inputs are necessary for the Pandemic Influenza Vaccine Market in 2025?
Key inputs include advanced technologies for vaccine development (e.g., mRNA technology), laboratory resources, skilled labor, regulatory approvals, and funding for research and development. Raw materials like antigens and equipment for mass production are also critical components.
What process steps are involved in the Pandemic Influenza Vaccine Market in 2025?
The process steps include research and development of the vaccine, clinical trials for safety and efficacy testing, regulatory approval from health authorities, manufacturing, distribution, and post-market surveillance to monitor effectiveness and safety.
Who are the customers of the Pandemic Influenza Vaccine Market in 2025?
The customers include government health agencies, healthcare providers, international organizations like the World Health Organization (WHO), and private organizations that manage vaccination programs. Additionally, the general public will be the end recipients of the vaccines.
What outputs will be delivered by the Pandemic Influenza Vaccine Market in 2025?
The outputs include safe, effective, and widely distributed influenza vaccines, along with educational materials and strategies to encourage vaccination. The market will also deliver data on vaccine effectiveness, epidemiological surveillance reports, and post-market safety monitoring.
Market Porter's Five Forces
How strong is the threat of new entrants in the Pandemic Influenza Vaccine Market in 2025?
The threat of new entrants is relatively low due to high barriers to entry, including significant capital investment, regulatory hurdles, and the need for specialized expertise in vaccine development. Established pharmaceutical companies have a strong foothold, making it challenging for new players to enter the market.
How intense is the bargaining power of suppliers in the Pandemic Influenza Vaccine Market in 2025?
The bargaining power of suppliers is moderate to high. Key suppliers of raw materials like antigens, adjuvants, and specialized manufacturing technologies are limited, which can give them more influence. However, large vaccine producers can often negotiate better terms due to their scale and buying power.
How strong is the bargaining power of buyers in the Pandemic Influenza Vaccine Market in 2025?
The bargaining power of buyers is moderate. While government health agencies and large organizations are significant buyers and may influence vaccine prices and terms, the limited number of suppliers and the specialized nature of the product restricts their power. Additionally, the global need for vaccines during pandemics limits buyer power.
What is the threat of substitute products in the Pandemic Influenza Vaccine Market in 2025?
The threat of substitutes is low. While alternative treatments for influenza exist, vaccines remain the most effective preventive measure. The lack of effective non-vaccine alternatives, especially during pandemics, keeps the threat from substitutes minimal.
How intense is the industry rivalry in the Pandemic Influenza Vaccine Market in 2025?
Industry rivalry is high. The market is dominated by a few large pharmaceutical companies, leading to intense competition for market share, especially in the wake of global health crises. This competition is driven by the urgency to develop effective vaccines quickly and secure government contracts and international approvals.
Market Upstream Analysis
What are the key upstream components influencing the Pandemic Influenza Vaccine Market in 2025?
The key upstream components include raw materials like antigens, adjuvants, and excipients, as well as the technological capabilities for vaccine production, such as mRNA platforms and traditional vaccine production methods. Additionally, the availability of skilled labor and expertise in vaccine development plays a crucial role.
How do suppliers impact the Pandemic Influenza Vaccine Market in 2025?
Suppliers of raw materials, such as antigens, bioreactors, and specialized manufacturing equipment, significantly impact the market by determining the quality, cost, and availability of essential components for vaccine development. Delays or shortages in the supply of these materials can hinder the timely production of vaccines.
How does research and development influence the upstream dynamics of the Pandemic Influenza Vaccine Market in 2025?
Research and development are critical upstream drivers, as advancements in vaccine technologies—such as mRNA or next-generation vaccine platforms—are key to improving the efficacy and speed of vaccine production. Investment in R&D ensures that vaccines are developed faster and more efficiently, addressing the evolving nature of influenza viruses.
What role does regulatory approval play in the upstream segment of the Pandemic Influenza Vaccine Market in 2025?
Regulatory approval is a key upstream factor, as the approval process sets the standards for vaccine development, testing, and safety. Stringent regulatory requirements can slow down vaccine rollout, while efficient regulatory pathways can speed up vaccine access, particularly during a pandemic.
How does the availability of manufacturing capabilities affect the upstream market for Pandemic Influenza Vaccines in 2025?
The availability of robust manufacturing capabilities, both in terms of infrastructure and capacity, directly impacts the speed and scale at which vaccines can be produced. Partnerships with contract manufacturers and scaling production capacity are essential to meeting the global demand for vaccines during pandemic outbreaks.
Market Midstream Analysis
What are the key midstream activities in the Pandemic Influenza Vaccine Market in 2025?
Key midstream activities include the manufacturing, quality control, and packaging of the influenza vaccines. This stage involves ensuring the vaccines meet regulatory standards, optimizing production efficiency, and preparing them for distribution to various markets.
How do logistics and distribution impact the midstream phase of the Pandemic Influenza Vaccine Market in 2025?
Logistics and distribution are critical in the midstream phase, as vaccines need to be transported globally, often under stringent temperature controls. Efficient logistics networks are necessary to ensure timely delivery to healthcare providers, governments, and emergency response teams.
What role does technology play in the midstream phase of the Pandemic Influenza Vaccine Market in 2025?
Technology plays a vital role in improving the efficiency of vaccine manufacturing, ensuring high-quality production, and maintaining cold chain integrity during transportation. Automation and data management technologies are key to optimizing production timelines and minimizing errors in the distribution process.
How does quality assurance affect the midstream process in the Pandemic Influenza Vaccine Market in 2025?
Quality assurance ensures that the vaccines are safe, effective, and meet regulatory standards. Strict quality control measures throughout production and pre-shipment inspections are essential to prevent contamination or inconsistencies, ensuring public trust in the vaccine's safety and efficacy.
What are the challenges faced during the midstream phase of the Pandemic Influenza Vaccine Market in 2025?
Challenges include maintaining consistent vaccine supply to meet global demand, managing complex cold chain logistics, and addressing potential production bottlenecks. Additionally, disruptions due to geopolitical issues, transportation delays, or resource shortages can hinder the smooth delivery of vaccines.
Market Downstream Analysis
What are the key downstream activities in the Pandemic Influenza Vaccine Market in 2025?
Key downstream activities include the distribution of vaccines to healthcare providers, public health organizations, and vaccination centers. This stage also involves administering vaccines to populations, monitoring vaccine effectiveness, and managing post-vaccination side effects through ongoing surveillance.
How does the role of healthcare providers influence the downstream phase of the Pandemic Influenza Vaccine Market in 2025?
Healthcare providers play a crucial role in the downstream phase by administering the vaccines to patients, providing education on vaccine benefits, and addressing concerns related to safety and efficacy. Their trust and communication with the public are essential for ensuring high vaccination rates.
What impact does public awareness and education have in the downstream phase of the Pandemic Influenza Vaccine Market in 2025?
Public awareness and education significantly influence the success of vaccine distribution. Effective communication about the importance of vaccination, addressing vaccine hesitancy, and providing transparent information on vaccine safety will lead to higher uptake and better protection against pandemics.
How does government involvement affect the downstream process in the Pandemic Influenza Vaccine Market in 2025?
Governments play a critical role by organizing mass vaccination campaigns, securing funding for vaccine purchases, and implementing policies to ensure equitable distribution. Their support is vital to ensure that vaccines reach underserved and vulnerable populations in a timely manner.
What are the challenges faced during the downstream phase of the Pandemic Influenza Vaccine Market in 2025?
Challenges include vaccine distribution delays, logistical hurdles in reaching remote areas, managing vaccine hesitancy, and addressing concerns over vaccine safety. Ensuring equitable access in low-income regions and monitoring the long-term efficacy and safety of vaccines are also significant concerns.
Chapter 1, to describe Pandemic Influenza Vaccine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Pandemic Influenza Vaccine, with price, sales, revenue and global market share of Pandemic Influenza Vaccine from 2018 to 2023.
Chapter 3, the Pandemic Influenza Vaccine competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Pandemic Influenza Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Pandemic Influenza Vaccine market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Pandemic Influenza Vaccine.
Chapter 14 and 15, to describe Pandemic Influenza Vaccine sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
1.1 Product Overview and Scope of Pandemic Influenza Vaccine
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Pandemic Influenza Vaccine Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Trivalent Influenza Vaccine
1.3.3 Quadrivalent Influenza Vaccine
1.4 Market Analysis by Application
1.4.1 Overview: Global Pandemic Influenza Vaccine Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 6 Months to 3 Years
1.4.3 > 3 Years
1.5 Global Pandemic Influenza Vaccine Market Size & Forecast
1.5.1 Global Pandemic Influenza Vaccine Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Pandemic Influenza Vaccine Sales Quantity (2018-2029)
1.5.3 Global Pandemic Influenza Vaccine Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Sanofi
2.1.1 Sanofi Details
2.1.2 Sanofi Major Business
2.1.3 Sanofi Pandemic Influenza Vaccine Product and Services
2.1.4 Sanofi Pandemic Influenza Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Sanofi Recent Developments/Updates
2.2 CSL
2.2.1 CSL Details
2.2.2 CSL Major Business
2.2.3 CSL Pandemic Influenza Vaccine Product and Services
2.2.4 CSL Pandemic Influenza Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 CSL Recent Developments/Updates
2.3 GSK
2.3.1 GSK Details
2.3.2 GSK Major Business
2.3.3 GSK Pandemic Influenza Vaccine Product and Services
2.3.4 GSK Pandemic Influenza Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 GSK Recent Developments/Updates
2.4 Viatris
2.4.1 Viatris Details
2.4.2 Viatris Major Business
2.4.3 Viatris Pandemic Influenza Vaccine Product and Services
2.4.4 Viatris Pandemic Influenza Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Viatris Recent Developments/Updates
2.5 AstraZeneca
2.5.1 AstraZeneca Details
2.5.2 AstraZeneca Major Business
2.5.3 AstraZeneca Pandemic Influenza Vaccine Product and Services
2.5.4 AstraZeneca Pandemic Influenza Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 AstraZeneca Recent Developments/Updates
2.6 Hualan Bio
2.6.1 Hualan Bio Details
2.6.2 Hualan Bio Major Business
2.6.3 Hualan Bio Pandemic Influenza Vaccine Product and Services
2.6.4 Hualan Bio Pandemic Influenza Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Hualan Bio Recent Developments/Updates
2.7 Changchun Institute of Biological
2.7.1 Changchun Institute of Biological Details
2.7.2 Changchun Institute of Biological Major Business
2.7.3 Changchun Institute of Biological Pandemic Influenza Vaccine Product and Services
2.7.4 Changchun Institute of Biological Pandemic Influenza Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Changchun Institute of Biological Recent Developments/Updates
2.8 Sinovac
2.8.1 Sinovac Details
2.8.2 Sinovac Major Business
2.8.3 Sinovac Pandemic Influenza Vaccine Product and Services
2.8.4 Sinovac Pandemic Influenza Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Sinovac Recent Developments/Updates
2.9 BCHT
2.9.1 BCHT Details
2.9.2 BCHT Major Business
2.9.3 BCHT Pandemic Influenza Vaccine Product and Services
2.9.4 BCHT Pandemic Influenza Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 BCHT Recent Developments/Updates
2.10 Jiangsu GDK
2.10.1 Jiangsu GDK Details
2.10.2 Jiangsu GDK Major Business
2.10.3 Jiangsu GDK Pandemic Influenza Vaccine Product and Services
2.10.4 Jiangsu GDK Pandemic Influenza Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Jiangsu GDK Recent Developments/Updates
2.11 KM Biologics
2.11.1 KM Biologics Details
2.11.2 KM Biologics Major Business
2.11.3 KM Biologics Pandemic Influenza Vaccine Product and Services
2.11.4 KM Biologics Pandemic Influenza Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 KM Biologics Recent Developments/Updates
3 Competitive Environment: Pandemic Influenza Vaccine by Manufacturer
3.1 Global Pandemic Influenza Vaccine Sales Quantity by Manufacturer (2018-2023)
3.2 Global Pandemic Influenza Vaccine Revenue by Manufacturer (2018-2023)
3.3 Global Pandemic Influenza Vaccine Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Pandemic Influenza Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Pandemic Influenza Vaccine Manufacturer Market Share in 2022
3.4.2 Top 6 Pandemic Influenza Vaccine Manufacturer Market Share in 2022
3.5 Pandemic Influenza Vaccine Market: Overall Company Footprint Analysis
3.5.1 Pandemic Influenza Vaccine Market: Region Footprint
3.5.2 Pandemic Influenza Vaccine Market: Company Product Type Footprint
3.5.3 Pandemic Influenza Vaccine Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Pandemic Influenza Vaccine Market Size by Region
4.1.1 Global Pandemic Influenza Vaccine Sales Quantity by Region (2018-2029)
4.1.2 Global Pandemic Influenza Vaccine Consumption Value by Region (2018-2029)
4.1.3 Global Pandemic Influenza Vaccine Average Price by Region (2018-2029)
4.2 North America Pandemic Influenza Vaccine Consumption Value (2018-2029)
4.3 Europe Pandemic Influenza Vaccine Consumption Value (2018-2029)
4.4 Asia-Pacific Pandemic Influenza Vaccine Consumption Value (2018-2029)
4.5 South America Pandemic Influenza Vaccine Consumption Value (2018-2029)
4.6 Middle East and Africa Pandemic Influenza Vaccine Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Pandemic Influenza Vaccine Sales Quantity by Type (2018-2029)
5.2 Global Pandemic Influenza Vaccine Consumption Value by Type (2018-2029)
5.3 Global Pandemic Influenza Vaccine Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Pandemic Influenza Vaccine Sales Quantity by Application (2018-2029)
6.2 Global Pandemic Influenza Vaccine Consumption Value by Application (2018-2029)
6.3 Global Pandemic Influenza Vaccine Average Price by Application (2018-2029)
7 North America
7.1 North America Pandemic Influenza Vaccine Sales Quantity by Type (2018-2029)
7.2 North America Pandemic Influenza Vaccine Sales Quantity by Application (2018-2029)
7.3 North America Pandemic Influenza Vaccine Market Size by Country
7.3.1 North America Pandemic Influenza Vaccine Sales Quantity by Country (2018-2029)
7.3.2 North America Pandemic Influenza Vaccine Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Pandemic Influenza Vaccine Sales Quantity by Type (2018-2029)
8.2 Europe Pandemic Influenza Vaccine Sales Quantity by Application (2018-2029)
8.3 Europe Pandemic Influenza Vaccine Market Size by Country
8.3.1 Europe Pandemic Influenza Vaccine Sales Quantity by Country (2018-2029)
8.3.2 Europe Pandemic Influenza Vaccine Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Pandemic Influenza Vaccine Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Pandemic Influenza Vaccine Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Pandemic Influenza Vaccine Market Size by Region
9.3.1 Asia-Pacific Pandemic Influenza Vaccine Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Pandemic Influenza Vaccine Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Pandemic Influenza Vaccine Sales Quantity by Type (2018-2029)
10.2 South America Pandemic Influenza Vaccine Sales Quantity by Application (2018-2029)
10.3 South America Pandemic Influenza Vaccine Market Size by Country
10.3.1 South America Pandemic Influenza Vaccine Sales Quantity by Country (2018-2029)
10.3.2 South America Pandemic Influenza Vaccine Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Pandemic Influenza Vaccine Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Pandemic Influenza Vaccine Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Pandemic Influenza Vaccine Market Size by Country
11.3.1 Middle East & Africa Pandemic Influenza Vaccine Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Pandemic Influenza Vaccine Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Pandemic Influenza Vaccine Market Drivers
12.2 Pandemic Influenza Vaccine Market Restraints
12.3 Pandemic Influenza Vaccine Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
13.1 Raw Material of Pandemic Influenza Vaccine and Key Manufacturers
13.2 Manufacturing Costs Percentage of Pandemic Influenza Vaccine
13.3 Pandemic Influenza Vaccine Production Process
13.4 Pandemic Influenza Vaccine Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Pandemic Influenza Vaccine Typical Distributors
14.3 Pandemic Influenza Vaccine Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
List of Tables
Table 1. Global Pandemic Influenza Vaccine Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Pandemic Influenza Vaccine Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Sanofi Basic Information, Manufacturing Base and Competitors
Table 4. Sanofi Major Business
Table 5. Sanofi Pandemic Influenza Vaccine Product and Services
Table 6. Sanofi Pandemic Influenza Vaccine Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Sanofi Recent Developments/Updates
Table 8. CSL Basic Information, Manufacturing Base and Competitors
Table 9. CSL Major Business
Table 10. CSL Pandemic Influenza Vaccine Product and Services
Table 11. CSL Pandemic Influenza Vaccine Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. CSL Recent Developments/Updates
Table 13. GSK Basic Information, Manufacturing Base and Competitors
Table 14. GSK Major Business
Table 15. GSK Pandemic Influenza Vaccine Product and Services
Table 16. GSK Pandemic Influenza Vaccine Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. GSK Recent Developments/Updates
Table 18. Viatris Basic Information, Manufacturing Base and Competitors
Table 19. Viatris Major Business
Table 20. Viatris Pandemic Influenza Vaccine Product and Services
Table 21. Viatris Pandemic Influenza Vaccine Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Viatris Recent Developments/Updates
Table 23. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 24. AstraZeneca Major Business
Table 25. AstraZeneca Pandemic Influenza Vaccine Product and Services
Table 26. AstraZeneca Pandemic Influenza Vaccine Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. AstraZeneca Recent Developments/Updates
Table 28. Hualan Bio Basic Information, Manufacturing Base and Competitors
Table 29. Hualan Bio Major Business
Table 30. Hualan Bio Pandemic Influenza Vaccine Product and Services
Table 31. Hualan Bio Pandemic Influenza Vaccine Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Hualan Bio Recent Developments/Updates
Table 33. Changchun Institute of Biological Basic Information, Manufacturing Base and Competitors
Table 34. Changchun Institute of Biological Major Business
Table 35. Changchun Institute of Biological Pandemic Influenza Vaccine Product and Services
Table 36. Changchun Institute of Biological Pandemic Influenza Vaccine Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Changchun Institute of Biological Recent Developments/Updates
Table 38. Sinovac Basic Information, Manufacturing Base and Competitors
Table 39. Sinovac Major Business
Table 40. Sinovac Pandemic Influenza Vaccine Product and Services
Table 41. Sinovac Pandemic Influenza Vaccine Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. Sinovac Recent Developments/Updates
Table 43. BCHT Basic Information, Manufacturing Base and Competitors
Table 44. BCHT Major Business
Table 45. BCHT Pandemic Influenza Vaccine Product and Services
Table 46. BCHT Pandemic Influenza Vaccine Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. BCHT Recent Developments/Updates
Table 48. Jiangsu GDK Basic Information, Manufacturing Base and Competitors
Table 49. Jiangsu GDK Major Business
Table 50. Jiangsu GDK Pandemic Influenza Vaccine Product and Services
Table 51. Jiangsu GDK Pandemic Influenza Vaccine Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 52. Jiangsu GDK Recent Developments/Updates
Table 53. KM Biologics Basic Information, Manufacturing Base and Competitors
Table 54. KM Biologics Major Business
Table 55. KM Biologics Pandemic Influenza Vaccine Product and Services
Table 56. KM Biologics Pandemic Influenza Vaccine Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 57. KM Biologics Recent Developments/Updates
Table 58. Global Pandemic Influenza Vaccine Sales Quantity by Manufacturer (2018-2023) & (M Units)
Table 59. Global Pandemic Influenza Vaccine Revenue by Manufacturer (2018-2023) & (USD Million)
Table 60. Global Pandemic Influenza Vaccine Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 61. Market Position of Manufacturers in Pandemic Influenza Vaccine, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 62. Head Office and Pandemic Influenza Vaccine Production Site of Key Manufacturer
Table 63. Pandemic Influenza Vaccine Market: Company Product Type Footprint
Table 64. Pandemic Influenza Vaccine Market: Company Product Application Footprint
Table 65. Pandemic Influenza Vaccine New Market Entrants and Barriers to Market Entry
Table 66. Pandemic Influenza Vaccine Mergers, Acquisition, Agreements, and Collaborations
Table 67. Global Pandemic Influenza Vaccine Sales Quantity by Region (2018-2023) & (M Units)
Table 68. Global Pandemic Influenza Vaccine Sales Quantity by Region (2024-2029) & (M Units)
Table 69. Global Pandemic Influenza Vaccine Consumption Value by Region (2018-2023) & (USD Million)
Table 70. Global Pandemic Influenza Vaccine Consumption Value by Region (2024-2029) & (USD Million)
Table 71. Global Pandemic Influenza Vaccine Average Price by Region (2018-2023) & (US$/Unit)
Table 72. Global Pandemic Influenza Vaccine Average Price by Region (2024-2029) & (US$/Unit)
Table 73. Global Pandemic Influenza Vaccine Sales Quantity by Type (2018-2023) & (M Units)
Table 74. Global Pandemic Influenza Vaccine Sales Quantity by Type (2024-2029) & (M Units)
Table 75. Global Pandemic Influenza Vaccine Consumption Value by Type (2018-2023) & (USD Million)
Table 76. Global Pandemic Influenza Vaccine Consumption Value by Type (2024-2029) & (USD Million)
Table 77. Global Pandemic Influenza Vaccine Average Price by Type (2018-2023) & (US$/Unit)
Table 78. Global Pandemic Influenza Vaccine Average Price by Type (2024-2029) & (US$/Unit)
Table 79. Global Pandemic Influenza Vaccine Sales Quantity by Application (2018-2023) & (M Units)
Table 80. Global Pandemic Influenza Vaccine Sales Quantity by Application (2024-2029) & (M Units)
Table 81. Global Pandemic Influenza Vaccine Consumption Value by Application (2018-2023) & (USD Million)
Table 82. Global Pandemic Influenza Vaccine Consumption Value by Application (2024-2029) & (USD Million)
Table 83. Global Pandemic Influenza Vaccine Average Price by Application (2018-2023) & (US$/Unit)
Table 84. Global Pandemic Influenza Vaccine Average Price by Application (2024-2029) & (US$/Unit)
Table 85. North America Pandemic Influenza Vaccine Sales Quantity by Type (2018-2023) & (M Units)
Table 86. North America Pandemic Influenza Vaccine Sales Quantity by Type (2024-2029) & (M Units)
Table 87. North America Pandemic Influenza Vaccine Sales Quantity by Application (2018-2023) & (M Units)
Table 88. North America Pandemic Influenza Vaccine Sales Quantity by Application (2024-2029) & (M Units)
Table 89. North America Pandemic Influenza Vaccine Sales Quantity by Country (2018-2023) & (M Units)
Table 90. North America Pandemic Influenza Vaccine Sales Quantity by Country (2024-2029) & (M Units)
Table 91. North America Pandemic Influenza Vaccine Consumption Value by Country (2018-2023) & (USD Million)
Table 92. North America Pandemic Influenza Vaccine Consumption Value by Country (2024-2029) & (USD Million)
Table 93. Europe Pandemic Influenza Vaccine Sales Quantity by Type (2018-2023) & (M Units)
Table 94. Europe Pandemic Influenza Vaccine Sales Quantity by Type (2024-2029) & (M Units)
Table 95. Europe Pandemic Influenza Vaccine Sales Quantity by Application (2018-2023) & (M Units)
Table 96. Europe Pandemic Influenza Vaccine Sales Quantity by Application (2024-2029) & (M Units)
Table 97. Europe Pandemic Influenza Vaccine Sales Quantity by Country (2018-2023) & (M Units)
Table 98. Europe Pandemic Influenza Vaccine Sales Quantity by Country (2024-2029) & (M Units)
Table 99. Europe Pandemic Influenza Vaccine Consumption Value by Country (2018-2023) & (USD Million)
Table 100. Europe Pandemic Influenza Vaccine Consumption Value by Country (2024-2029) & (USD Million)
Table 101. Asia-Pacific Pandemic Influenza Vaccine Sales Quantity by Type (2018-2023) & (M Units)
Table 102. Asia-Pacific Pandemic Influenza Vaccine Sales Quantity by Type (2024-2029) & (M Units)
Table 103. Asia-Pacific Pandemic Influenza Vaccine Sales Quantity by Application (2018-2023) & (M Units)
Table 104. Asia-Pacific Pandemic Influenza Vaccine Sales Quantity by Application (2024-2029) & (M Units)
Table 105. Asia-Pacific Pandemic Influenza Vaccine Sales Quantity by Region (2018-2023) & (M Units)
Table 106. Asia-Pacific Pandemic Influenza Vaccine Sales Quantity by Region (2024-2029) & (M Units)
Table 107. Asia-Pacific Pandemic Influenza Vaccine Consumption Value by Region (2018-2023) & (USD Million)
Table 108. Asia-Pacific Pandemic Influenza Vaccine Consumption Value by Region (2024-2029) & (USD Million)
Table 109. South America Pandemic Influenza Vaccine Sales Quantity by Type (2018-2023) & (M Units)
Table 110. South America Pandemic Influenza Vaccine Sales Quantity by Type (2024-2029) & (M Units)
Table 111. South America Pandemic Influenza Vaccine Sales Quantity by Application (2018-2023) & (M Units)
Table 112. South America Pandemic Influenza Vaccine Sales Quantity by Application (2024-2029) & (M Units)
Table 113. South America Pandemic Influenza Vaccine Sales Quantity by Country (2018-2023) & (M Units)
Table 114. South America Pandemic Influenza Vaccine Sales Quantity by Country (2024-2029) & (M Units)
Table 115. South America Pandemic Influenza Vaccine Consumption Value by Country (2018-2023) & (USD Million)
Table 116. South America Pandemic Influenza Vaccine Consumption Value by Country (2024-2029) & (USD Million)
Table 117. Middle East & Africa Pandemic Influenza Vaccine Sales Quantity by Type (2018-2023) & (M Units)
Table 118. Middle East & Africa Pandemic Influenza Vaccine Sales Quantity by Type (2024-2029) & (M Units)
Table 119. Middle East & Africa Pandemic Influenza Vaccine Sales Quantity by Application (2018-2023) & (M Units)
Table 120. Middle East & Africa Pandemic Influenza Vaccine Sales Quantity by Application (2024-2029) & (M Units)
Table 121. Middle East & Africa Pandemic Influenza Vaccine Sales Quantity by Region (2018-2023) & (M Units)
Table 122. Middle East & Africa Pandemic Influenza Vaccine Sales Quantity by Region (2024-2029) & (M Units)
Table 123. Middle East & Africa Pandemic Influenza Vaccine Consumption Value by Region (2018-2023) & (USD Million)
Table 124. Middle East & Africa Pandemic Influenza Vaccine Consumption Value by Region (2024-2029) & (USD Million)
Table 125. Pandemic Influenza Vaccine Raw Material
Table 126. Key Manufacturers of Pandemic Influenza Vaccine Raw Materials
Table 127. Pandemic Influenza Vaccine Typical Distributors
Table 128. Pandemic Influenza Vaccine Typical Customers
List of Figures
Figure 1. Pandemic Influenza Vaccine Picture
Figure 2. Global Pandemic Influenza Vaccine Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Pandemic Influenza Vaccine Consumption Value Market Share by Type in 2022
Figure 4. Trivalent Influenza Vaccine Examples
Figure 5. Quadrivalent Influenza Vaccine Examples
Figure 6. Global Pandemic Influenza Vaccine Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 7. Global Pandemic Influenza Vaccine Consumption Value Market Share by Application in 2022
Figure 8. 6 Months to 3 Years Examples
Figure 9. > 3 Years Examples
Figure 10. Global Pandemic Influenza Vaccine Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 11. Global Pandemic Influenza Vaccine Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 12. Global Pandemic Influenza Vaccine Sales Quantity (2018-2029) & (M Units)
Figure 13. Global Pandemic Influenza Vaccine Average Price (2018-2029) & (US$/Unit)
Figure 14. Global Pandemic Influenza Vaccine Sales Quantity Market Share by Manufacturer in 2022
Figure 15. Global Pandemic Influenza Vaccine Consumption Value Market Share by Manufacturer in 2022
Figure 16. Producer Shipments of Pandemic Influenza Vaccine by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 17. Top 3 Pandemic Influenza Vaccine Manufacturer (Consumption Value) Market Share in 2022
Figure 18. Top 6 Pandemic Influenza Vaccine Manufacturer (Consumption Value) Market Share in 2022
Figure 19. Global Pandemic Influenza Vaccine Sales Quantity Market Share by Region (2018-2029)
Figure 20. Global Pandemic Influenza Vaccine Consumption Value Market Share by Region (2018-2029)
Figure 21. North America Pandemic Influenza Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 22. Europe Pandemic Influenza Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 23. Asia-Pacific Pandemic Influenza Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 24. South America Pandemic Influenza Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 25. Middle East & Africa Pandemic Influenza Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 26. Global Pandemic Influenza Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 27. Global Pandemic Influenza Vaccine Consumption Value Market Share by Type (2018-2029)
Figure 28. Global Pandemic Influenza Vaccine Average Price by Type (2018-2029) & (US$/Unit)
Figure 29. Global Pandemic Influenza Vaccine Sales Quantity Market Share by Application (2018-2029)
Figure 30. Global Pandemic Influenza Vaccine Consumption Value Market Share by Application (2018-2029)
Figure 31. Global Pandemic Influenza Vaccine Average Price by Application (2018-2029) & (US$/Unit)
Figure 32. North America Pandemic Influenza Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 33. North America Pandemic Influenza Vaccine Sales Quantity Market Share by Application (2018-2029)
Figure 34. North America Pandemic Influenza Vaccine Sales Quantity Market Share by Country (2018-2029)
Figure 35. North America Pandemic Influenza Vaccine Consumption Value Market Share by Country (2018-2029)
Figure 36. United States Pandemic Influenza Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 37. Canada Pandemic Influenza Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 38. Mexico Pandemic Influenza Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 39. Europe Pandemic Influenza Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 40. Europe Pandemic Influenza Vaccine Sales Quantity Market Share by Application (2018-2029)
Figure 41. Europe Pandemic Influenza Vaccine Sales Quantity Market Share by Country (2018-2029)
Figure 42. Europe Pandemic Influenza Vaccine Consumption Value Market Share by Country (2018-2029)
Figure 43. Germany Pandemic Influenza Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 44. France Pandemic Influenza Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 45. United Kingdom Pandemic Influenza Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 46. Russia Pandemic Influenza Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. Italy Pandemic Influenza Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. Asia-Pacific Pandemic Influenza Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 49. Asia-Pacific Pandemic Influenza Vaccine Sales Quantity Market Share by Application (2018-2029)
Figure 50. Asia-Pacific Pandemic Influenza Vaccine Sales Quantity Market Share by Region (2018-2029)
Figure 51. Asia-Pacific Pandemic Influenza Vaccine Consumption Value Market Share by Region (2018-2029)
Figure 52. China Pandemic Influenza Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 53. Japan Pandemic Influenza Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 54. Korea Pandemic Influenza Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 55. India Pandemic Influenza Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. Southeast Asia Pandemic Influenza Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. Australia Pandemic Influenza Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. South America Pandemic Influenza Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 59. South America Pandemic Influenza Vaccine Sales Quantity Market Share by Application (2018-2029)
Figure 60. South America Pandemic Influenza Vaccine Sales Quantity Market Share by Country (2018-2029)
Figure 61. South America Pandemic Influenza Vaccine Consumption Value Market Share by Country (2018-2029)
Figure 62. Brazil Pandemic Influenza Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 63. Argentina Pandemic Influenza Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 64. Middle East & Africa Pandemic Influenza Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 65. Middle East & Africa Pandemic Influenza Vaccine Sales Quantity Market Share by Application (2018-2029)
Figure 66. Middle East & Africa Pandemic Influenza Vaccine Sales Quantity Market Share by Region (2018-2029)
Figure 67. Middle East & Africa Pandemic Influenza Vaccine Consumption Value Market Share by Region (2018-2029)
Figure 68. Turkey Pandemic Influenza Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 69. Egypt Pandemic Influenza Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 70. Saudi Arabia Pandemic Influenza Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 71. South Africa Pandemic Influenza Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. Pandemic Influenza Vaccine Market Drivers
Figure 73. Pandemic Influenza Vaccine Market Restraints
Figure 74. Pandemic Influenza Vaccine Market Trends
Figure 75. Porters Five Forces Analysis
Figure 76. Manufacturing Cost Structure Analysis of Pandemic Influenza Vaccine in 2022
Figure 77. Manufacturing Process Analysis of Pandemic Influenza Vaccine
Figure 78. Pandemic Influenza Vaccine Industrial Chain
Figure 79. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 80. Direct Channel Pros & Cons
Figure 81. Indirect Channel Pros & Cons
Figure 82. Methodology
Figure 83. Research Process and Data Source
